NCT00242736

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 350 (planned)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with esomeprazole (NEXIUM®) in those subjects with Erosive Esophagitis (EE) and those without EE.

Conditions

• GERD

Interventions

Type	Name	Description
DRUG	Esomeprazole

Timeline

• Start date: 2005-10-01
• Completion: 2006-01-01
• First posted: 2005-10-21
• Last updated: 2009-03-06

Locations

25 sites across 1 country: United States